$BNGO Cashflow Statement | Understand Stock

$BNGO

$1.22 +$0.06 (5.17%) Close

$BNGO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities:
Net Income Loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense
Goodwill impairment
Inventory write-offs
Amortization of financing lease right-of-use asset
Amortization of interest on securities
Non-cash interest expense
Accretion of interest on securities
Net realized loss on investments
Settlement of interest on debt
(Benefit) expense from deferred income taxes
Non-cash lease expense
Gain on lease modification
Stock-based compensation
Provision for bad debt expense
Gain on forgiveness of PPP Loan
Stock issued for services
Issue stock for covenant waiver
Warrant exercise pursuant to cashless exercise
Loss on debt extinguishment
Cost of leased equipment sold to customer
Client warranty exchange of fixed asset
Change in fair value of contingent consideration
Change in fair value of convertible debentures, convertible notes payable and option liability
Loss on High Trail Agreement
Loss on issuance of convertible debentures
Gain on High Trail extinguishment
Loss on extinguishment of convertible debentures payable
Disposal of internal-use software
Intangible assets and other long-lived assets impairment
Long-lived assets held for sale impairment
Right-of-use-asset impairment
Disposal of property and equipment
Contingent consideration cash payment in excess of acquisition-date fair value
Changes in operating assets and liabilities
Accounts receivable
Inventory
Prepaid expenses and other current assets
Other assets
Other long-term assets
Accounts payable
Accrued expenses, contract liabilities, and lease liabilities, net

Net cash used in operating activities
Investing activities:
BioDiscovery acquisition, return of purchase consideration from escrow
Purigen acquisition, return of purchase consideration from escrow
Purigen acquisition, net of cash acquired
Lineagen
BioDiscovery
Purigen acquisition
Total purigen acquisition, net of cash acquired

Purchases of property and equipment
Sale of property and equipment
Construction in process
Purchases of intangible assets
Payment of initial direct costs on lease
Purchase of available for sale securities
Sale and maturities of available for sale securities
Net cash provided by (used in) investing activities

Financing activities:
Repayment of term-loan debt
Principal payments of financing lease liability
Proceeds from PPP Loan
Proceeds from sale of common stock
Proceeds from sale of common stock and warrants
Proceeds from sale of common stock under employee stock purchase plan
Proceeds from warrant and option exercises
Proceeds from issuance of convertible debentures
Repayments of borrowing from line of credit
Payments on High Trail notes
Payments on convertible debentures
Debt issuance costs on sale of convertible debentures
Payments of retirement fees for redemption of High Trail notes
Contingent consideration milestone payment
Net cash provided by (used in) financing activities

Effect of exchange rates on cash and cash equivalents and restricted cash
Net decrease in cash and cash equivalents and restricted cash
Cash and cash equivalents and restricted cash at beginning of period
Cash and cash equivalents and restricted cash at end of period
Reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets to the total amounts reported on the consolidated statements of cash flows
Cash and cash equivalents
Money market funds classified as restricted cash and investments
Restricted cash
Total cash and cash equivalents and restricted cash at end of period
Supplemental disclosure of cash flow information
Cash paid for interest
Cash paid for operating lease liabilities
Supplemental disclosure of non-cash financing and investing activity
Fair value of common stock issued related to BioDiscovery acquisition
Lineagen
BioDiscovery
Total fair value of common stock issued related to BioDiscovery acquisition
Contingent consideration related to BioDiscovery acquisition
BioDiscovery
Purigen acquisition
Total contingent consideration related to BioDiscovery acquisition
Contingent consideration related to Purigen acquisition
Transfer of instruments and servers from inventory into property and equipment, net
Issuance of common stock for convertible debentures payable
Property and equipment included in accounts payable
Debt issuance costs included in accounts payable
Conversion of High Trail convertible notes payable into common stock at fair value
Accrued liability for fees to be paid in common stock
Fees paid in common stock
Operating lease liabilities resulting from obtaining right-of-use assets
Non-cash Fill-Up Amount

Comments